North China Pharmaceutical Group Corp:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:North China Pharmaceutical Group Corp - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10506
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
North China Pharmaceutical Group Corp (NCPC) is a healthcare products provider that manufactures and distributes formulation products, nutrition and health products, raw materials, and veterinary drugs. The company offers sirolimus capsules, clindamycin phosphate injection, mezlocillin sodium for injection, ampicillin sodium for injection, amoxicillin sulbactam pills, amoxicillin dispersible tablets, cyclosporin soft capsule mecobalamin tablets and rocuronium bromide injection. Its nutrition and health products comprise chewable tablets, anyixin tablets, isomaric syrup, xin yan capsule and soft capsule. NCPC offers products in dosage forms of capsules, granules, injections, freeze-dried powder for injection, immunologic and biologic agent, nutrition supplement, tablets, veterinary and biocides products, powder for injection, antineoplastic agents, oral suspension and other formulations. The company markets its products across China. NCPC is headquartered in Shijiazhuang, China.

North China Pharmaceutical Group Corp – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
Debt Offering 11
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 11
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 12
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 13
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 14
North China Pharma Announces Public Offering Of Notes For US$73 Million 15
Acquisition 16
NCPC To Sell North China Pharma Huasheng For US$12 Million 16
NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 17
NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 18
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 19
North China Pharmaceutical Group Corp – Key Competitors 20
North China Pharmaceutical Group Corp – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Key Facts 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 8
North China Pharma Receives Approval From China Securities Regulatory Commission For Private Placement Of Shares For US$183.4 Million 9
North China Pharma Completes Private Placement Of Shares For US$471 Million 10
North China Pharma to Raise USD44 Million in Private Placement of Bonds Due 2021 11
North China Pharma to Raise up to USD74 Million in Private Placement of Bonds Due 2021 12
North China Pharma Raises USD147 Million in Public Offering of 5.3% Bonds Due 2018 13
North China Pharmaceutical Plans to Raise USD108.2 Million in Public Offering of Bonds Due 2021 14
North China Pharma Announces Public Offering Of Notes For US$73 Million 15
NCPC To Sell North China Pharma Huasheng For US$12 Million 16
NCPC To Sell 39% Stake In Shenzhen Medicine Company For US$3 Million 17
NCPC To Acquire Remaining 50% Stake In NCPC Orchid Pharma For US$14 Million 18
North China Pharma To Acquire Remaining 50% Stake In Pharmaceutical Company For US$14.2 Million 19
North China Pharmaceutical Group Corp, Key Competitors 20
North China Pharmaceutical Group Corp, Subsidiaries 21

List of Figures
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
North China Pharmaceutical Group Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

★海外企業調査レポート[North China Pharmaceutical Group Corp:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • OraSolv AB (OS):企業の財務・戦略的SWOT分析
    OraSolv AB (OS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • SARIA AS GmbH & Co KG:企業の戦略的SWOT分析
    SARIA AS GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Hutchison China Meditech Ltd
    Hutchison China Meditech Ltd - Strategy, SWOT and Corporate Finance Report Summary Hutchison China Meditech Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Bord na Mona Plc:企業の戦略的SWOT分析
    Bord na Mona Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Yanbu National Petrochemicals Co (2290):企業の財務・戦略的SWOT分析
    Summary Yanbu National Petrochemicals Co (YANSAB), a subsidiary of Saudi Basic Industries Corp is a manufacturer and distributor of petrochemical products. The company offers products such as ethylene, linear density polyethylene, polypropylene, butene 1, ethylene glycol, polyethylene, butene 2, MTB …
  • Cepheid:医療機器:M&Aディール及び事業提携情報
    Summary Cepheid, a subsidiary of Danaher Corporation, is a molecular diagnostic company that develops, manufactures and markets molecular systems and tests for clinical and non-clinical markets. The company offers in vitro diagnostic tests for health care associated infections, critical infectious d …
  • IMV Inc (IMV):製薬・医療:M&Aディール及び事業提携情報
    Summary IMV Inc (IMV), formerly Immunovaccine Inc, is a clinical-stage biopharmaceutical company that develops cancer immunotherapies and infectious disease vaccines. The company’s product candidates include DPX-Survivac, a T cell activating immunotherapy that identifies and disrupts cancer biology …
  • Sky plc:企業のM&A・事業提携・投資動向
    Sky plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sky plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …
  • Personal Group Holdings Plc:企業の戦略・SWOT・財務情報
    Personal Group Holdings Plc - Strategy, SWOT and Corporate Finance Report Summary Personal Group Holdings Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • UMW Holdings Berhad (UMW):石油・ガス:M&Aディール及び事業提携情報
    Summary UMW Holdings Bhd (UMW) is a diversified company. The company operates through its business divisions such as automotive, equipment, manufacturing and engineering, and oil and gas. Its automotive business manufactures, assembles, markets and distributes passenger cars and commercial vehicles. …
  • Acuity Brands, Inc.:企業の戦略・SWOT・財務分析
    Acuity Brands, Inc. - Strategy, SWOT and Corporate Finance Report Summary Acuity Brands, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Larsen & Toubro Limited:企業の戦略・SWOT・財務情報
    Larsen & Toubro Limited - Strategy, SWOT and Corporate Finance Report Summary Larsen & Toubro Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Macquarie Group Ltd:企業のM&A・事業提携・投資動向
    Macquarie Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Macquarie Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Balaji Amines Ltd (BALAMINES):企業の財務・戦略的SWOT分析
    Balaji Amines Ltd (BALAMINES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Jones Packaging Inc.:企業の戦略的SWOT分析
    Jones Packaging Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Arix Bioscience Plc (ARIX):企業の財務・戦略的SWOT分析
    Arix Bioscience Plc (ARIX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Surgical Care Affiliates LLC (SCAI):企業の財務・戦略的SWOT分析
    Summary Surgical Care Affiliates LLC (SCA), a subsidiary of UnitedHealth Group Inc is a healthcare organization that offers patient care and healthcare services. The organization's services include scheduling optimization, physician governance and engagement, case costing, profitability analysis and …
  • PRA Health Sciences Inc (PRAH):製薬・医療:M&Aディール及び事業提携情報
    Summary PRA Health Sciences Inc (PRA) is a contract research organization (CRO) which provides clinical development services. The company offers services such as phase I-IV study management, and embedded and functional outsourcing services. It offers solutions in bioanalytical laboratories, biometri …
  • Ascom Holding AG:企業のM&A・事業提携・投資動向
    Ascom Holding AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Ascom Holding AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Leukocare AG:医療機器:M&Aディール及び事業提携情報
    Summary Leukocare AG (Leukocare) is a clinical-stage biotechnology company that offers technologies for stabilizing proteins to increase shelf-life and to facilitate terminal sterilization by irradiation or gas. The company’s services include development of spray drying and spray freeze-drying proce …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆